How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?
The content on this page is not current guidance and is only for the purposes of the consultation process.

1 Recommendations

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about Idebenone

Marketing authorisation indication

2.1

Idebenone (Raxone, Chiesi) is indicated for the 'treatment of visual impairment in adolescent and adult patients with Leber's hereditary optic neuropathy (LHON)'.

Dosage in the marketing authorisation

2.2

The dosage schedule is available in the idebenone.

Price

2.3

The list price for a 180 tablets pack of 150 mg idebenone is £6,364 (excluding VAT; BNF online, accessed April 2024).

2.4

The company has a commercial arrangement, which would have applied if idebenone had been recommended.